Lynch Syndrome Increases Risk of Pancreatic Cancer

By CancerConsultants.com
 

Lynch Syndrome, an inherited cause of colorectal cancer that also increases the risk of several other types of cancer, results in a risk of pancreatic cancer that is several times higher than the risk in the general population. These results were published in the Journal of the American Medical Association.

Lynch Syndrome is also known as hereditary nonpolyposis colorectal cancer (HNPCC). It results from inherited mutations in genes involved in DNA mismatch repair. These mutations greatly increase the risk of developing colorectal cancer and also increase the risk of several other cancers.

Average age at diagnosis of colorectal cancer is 44 years in individuals with an HNPCC mutation compared with 64 years in the general population. Other cancers that are more common in families with Lynch Syndrome include cancers of the endometrium (the lining of the uterus), ovary, small intestine, ureter, and renal pelvis. 

Pancreatic cancer may also be more common in families with Lynch Syndrome, but the risk has been uncertain. To explore the frequency of pancreatic cancer in families with Lynch Syndrome, researchers evaluated information from 6,342 individuals from 147 families with Lynch Syndrome.

  • 21% of the families reported at least one case of pancreatic cancer.
  • The risk of pancreatic cancer in families with Lynch Syndrome was 1.31% by the age of 50 and 3.68% by the age of 70. This risk is more than eight times higher than the risk in the general U.S. population.

The results of this study confirm that Lynch Syndrome is linked with an increased risk of pancreatic cancer and provide estimates regarding the lifetime risk of pancreatic cancer among affected family members.

Reference: Kastrinos F, Mukherjee B, Tayob N et al. Risk of pancreatic cancer in families with Lynch Syndrome. Journal of the American Medical Association. 2009;302:1790-1795.

Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health